{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-028226","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2025-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.384014+00:00","generated_at":"2026-05-24T05:14:59.814143+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Journey Medical reports FY2024 revenue $56.1M, net loss $14.7M; Emrosi launch underway","bullets":["Total revenue $56.1M, down 29% YoY; product revenue net $55.1M (-8%) due to higher rebates and lower legacy volumes.","Net loss $14.7M ($0.72/sh) vs $3.9M loss prior year; adjusted EBITDA $0.8M vs $15.6M.","FDA approved Emrosi (minocycline) for rosacea Nov 2024; distribution started, first prescriptions filled, full promo expected April 2025.","Met all 2024 financial guidance: product revenue $55-60M, SG&A $39-42M, R&D $9-10M.","Non-GAAP adjusted EBITDA per share $0.04 basic, $0.03 diluted."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-028226","json":"https://secwatch.observer/filing/0001104659-25-028226.json","markdown":"https://secwatch.observer/filing/0001104659-25-028226.md","text":"https://secwatch.observer/filing/0001104659-25-028226.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465925028226/0001104659-25-028226-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465925028226/tm2510555d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:14:59.814143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}